The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

Haematologica. 2017 Sep;102(9):e364-e367. doi: 10.3324/haematol.2017.168872. Epub 2017 May 26.

Authors

Sharmilan Thanendrarajan¹, Erming Tian¹, Pingping Qu¹, Pankaj Mathur¹, Carolina Schinke¹, Frits van Rhee¹, Maurizio Zangari¹, Leo Rasche¹, Niels Weinhold¹, Daisy Alapat², William Bellamy², Cody Ashby¹, Sandra Mattox¹, Joshua Epstein¹, Shmuel Yaccoby¹, Bart Barlogie¹, Antje Hoering³, Michael Bauer¹, Brian A Walker¹, Faith E Davies¹, Gareth J Morgan⁴

Affiliations

¹ Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
² Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
³ Cancer Research and Biostatistics, Seattle, WA, USA.
⁴ Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA gjmorgan@uams.edu.

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Chromosome Deletion*
Chromosomes, Human, Pair 17*
Humans
Multiple Myeloma / genetics*
Multiple Myeloma / mortality
Survival Analysis
Treatment Outcome
Tumor Suppressor Protein p53 / metabolism*

Substances

TP53 protein, human
Tumor Suppressor Protein p53